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Abstract
!
Classical multicomponent preparations mostly
derived from traditional usages in Western and
Eastern phytotherapy have been under-evaluated
for a long time as potential new pharmaceutical
products. The regulatory scenario, in particular
at the European level, has only recently consid-
ered these aspects proposing harmonized guide-
lines for the pharmaceutical registration of tradi-
tional herbal products. Nevertheless, a specific
regulation for innovative products based on the
combination of precious knowledge arising from
traditional usages andmodern scientific advance-
ments is still missing. In this paper, we propose a
critical review of the current situation with the
specific aim of contributing to create a more fa-
vorable regulatory environment for the pharma-
ceutical registration of new and innovative herbal
medicinal products.
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l.Introduction
!
Since the early history of medicine and up until
the 20th century, therapeutic aids have been
almost exclusively based on multicomponent
products obtained from natural sources, includ-
ing botanical derivatives as an important part.
Only at the beginning of the 20th century, gener-
ations of Western medicine scientists, mostly in-
spired by Paul Ehrlichʼs “magic bullet” paradigm,
started to spend all their efforts in finding new,
powerful therapeutic compounds aimed at clearly
defined molecular targets. This approach, mainly
based on HTS applied to natural, semisynthetic,
and total synthetic derivatives, has been devel-
oped for decades throughout the past 50 years
and is mainly focused on the combination of the
concepts of “maximal selectivity” and “maximal
potency”. This paradigmatic approach has repre-
sented an unchanged milestone in the context ofMinghetti P et al. Idrug discovery and development in the last
decades and has undoubtedly yielded successful
drugs, like microtubule-targeting anticancer
agents (taxol, taxotere, ixabepilon), selective pro-
ton-pump inhibitors (R-lansoprazole), and EGFR-
tyrosine kinase inhibitors (iressa). Even looking at
this scenario of single new molecules introduced
into the pharmaceutical market, it is worth to
consider that natural sourcing played amajor role
in recent years as well. From 1983 to 1994, about
40% of novel drugs approved in North America
were derived from natural compounds and ap-
proximately 70% of the new chemical entities
reported between 1981 and mid-2006 arose from
research on natural products [1].
In spite of this impressive effort, the rate of ap-
proval of new drugs, mainly discovered and de-
veloped following the approach described above,
has declined markedly in the last 20 years. Main
reasons were failure due to lack of efficacy in thennovation in Phytotherapy:… Planta Med 2016; 82: 591–595
Table 1 Comparison among possible drugs derived from plants and the modules of CTD required.
THMP Well-established use
(WEU)
Innovative-
drug
Copy of full dossier
drug
THMP with some
innovation
CTD Simplified Bibliographical Complete Simplified Hybrid
CTD: Module 3 (quality) Full Full Full Full Full
CTD: Module 4 (safety) – Full (Bibliographical) Full – To evaluate case by case
CTD: Module 5 (efficacy) – Full (Bibliographical) Full Bioequivalence study To evaluate case by case
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l.advanced phase of clinical testing and/or presence of important
side effects [2].
In addition, evidence is steadily increasing that due to their com-
plex etiopathogenesis, a number of relevant diseases require
combination therapy, which may include several single-compo-
nent drugs. Combination therapy is usually designed both to
modulate multiple processes involved in the disease and also to
reduce resistance, which is commonly induced by a single-agent
treatment. Combination therapy plays a particularly important
role in the treatment of infectious diseases such as HIV, tubercu-
losis, and malaria and complex chronic diseases like cancer,
atherosclerosis, andmetabolic syndrome. In this context, another
concept gaining favor is that an approach strictly linked to HTS
may only select interesting compounds with high activity, whose
affinity to a target enzyme or receptor is strong but, on the con-
trary, it would be undoubtedly missing any prodrug and, more
importantly, potential synergism among active principles in the
same multicomponent product [3,4].
All these issues are a matter of current discussion within the
scientific community, which is wondering whether bioactive
mixtures of natural products should be conceptually and con-
cretely reconsidered for the development of new therapeutic
approaches. This “rethinking” has also been fueled by the recent
wave of reevaluation of Eastern traditional medical systems such
as traditional Chinese medicine (TCM) and Indian Ayurveda, due
to increasing popularity [5]. These approaches, indeed, are more
oriented to consider natural product mixtures more appropriate
to prevent and treat complex, pleiotropic diseases than single ac-
tive pharmaceuticals. Nevertheless, even within Western tradi-
tional phytotherapy, the old concept of “phyto-complex” was
strictly linked to the identification of the active principle as a
multiplicity of molecules rather than a single component of the
mixture. From this perspective, it has to be noted that many
attempts to identify the single actually working active principle
have failed [(i.e., Ginkgo biloba L. (Ginkgoaceae), Hypericum per-
foratum L. (Hypericaceae), Panax ginseng C.A.Mey. (Araliaceae),
Valeriana officinalis L. (Caprifoliaceae)]. Taking into account that
traditional medicine, which often includes complex botanical
derivatives, is as an extremely rich source of potential innovation
in the pharmaceutical area, a great expectation arises constantly
in the scientific and pharmaceutical industry community, but in
most cases such expectation is frustrated by the constraints of
the regulatory systems. Actually, these are mainly oriented to
the classical “magic bullet” approach and consequently prefer
the time-consuming strategy of identifying the active principles
of a complex mixture and further developing them according to
the regular mainstream pharmaceutical rules. In the best cases,
they accept a multicomponent product as a pharmaceutical
entity, but impose a discouraging first-line safety and efficacy
assessment, which most often hampers the development of the
product. Moreover, an additional discouraging factor is the fact
that in some cases the products can be put on the market asMinghetti P et al. Innovation in Phytotherapy:… Planta Med 2016; 82: 591–595“food” (i.e., health food or food supplement) [6,7] and marketed
with claims sometimes ”mimicking” the therapeutic effect, or as
if they were medical devices with claims which are really super-
imposable to those of medicinal products.
The discussion on the potential of complex natural product mix-
tures is also positively influenced by the undeniable advance-
ment in the field of available analytical technologies which, be-
sides the currently used sensitive and selective variants of TLC,
GC, and HPLC, can also include additional methodologies such as
combined chromatography-mass spectrometry and even com-
bined chromatography-NMR. When applied to multicomponent
products, these techniques can really allow a detailed definition
of their composition [8,9]. These approaches are also an effective
tool to prepare lab-scale, pilot-scale and definitely industrial-
scale batches of rigorously reproducible standardized products
satisfying all pharmaceutical grade requirements for preclinical/
clinical development and subsequent marketing authorization.
Considering the points above, and based on the level reached by
technological and scientific knowledge on HMPs, we really won-
der whether a new approach can be considered at the European
regulatory level in order to allow a simplified pharmaceutical
development for innovative HMPs and therefore increase the
number of safe and effective products on the market. In particu-
lar, our suggestion is to consider that a more favorable regulatory
environment could help establish a faster approach to the clinical
development of innovative HMPs aimed at improving the thera-
peutic index of traditionally utilized products, meaning in detail:
" New standardization method focused on active principles re-
cently proved to be pivotal for the effect.
" Removal of undesired compounds.
" Improvement of oral bioavaibility.
" Rational combinations with other HMPs for new therapeutic
targets.Regulatory Aspects
!
As of today, in order to reach the market, according to European
medicine legislation (Directive 2001/83/EC as amended by Direc-
tive 2004/24/EC), medicinal products containing herbal sub-
stances/preparations must fall within one of the following five
categories (l" Table 1):
1. A product can be a traditional herbal medicinal product if it
has a traditional use and sufficient safety data and plausible
efficacy. This product can be registered through a simplified
registration procedure (article 16a) [10].
2. A medicinal product can be considered well established if, ac-
cording to scientific literature, the applicant can demonstrate
that the active substances have had a well-established medici-
nal use in EU for at least 10 years, and have a recognized effi-
cacy and an acceptable level of safety. The product can be au-
thorized through a full bibliographic CTD (article 10a).
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l.3. A product including new active substances can be marketed
only after a competent authorityʼs evaluation of safety and effi-
cacy data resulting from the company development program.
The product can be authorized through a full CTD (article 8).
4. A product can be considered a copy if it has the same qualita-
tive and quantitative composition in active substances, the
same pharmaceutical form, and bioequivalence (demonstrated
by appropriate bioavailability) to the reference product. In this
case, it can be authorized through a simplified CTD [article 10
(1)].
Historically, the regulatory approach to herbal substances and
preparations has been controversial within the European coun-
tries, and several products classified differently as drugs, food
and dietary supplements, cosmetics, and medical devices coexist
on the market. Then, aiming to harmonize the regulation of such
natural products, the European Parliament issued Directive
2004/24/EC, amending, with regard to THMPs, the Directive n.
2001/83/EC about a community code relating to herbal products
presenting therapeutic claims [11]. According to this directive, a
simplified pharmaceutical registration could be granted to herbal
medicinal products with a history of traditional use in Europe.
Considering this last change, two classes of HMPs are today le-
gally recognized in Europe: WEU and THMPs. WEU are those
HMPs with proven clinical efficacy and at least ten years use in
the European Union. THMPs (introduced for the first time by Di-
rective 2004/24/EC) do not need to provide clinical data in the
registration dossier. Their features are the following:
" Traditional usage for at least 30 years, of which at least 15 is in
the European Community.
" Oral, external, or inhaled use.
" Self-medication drugs: the intervention of a medical doctor
should not be required for diagnosis, drug prescription, and
therapy follow-up.
" Therapeutic indications are appropriate for THMPs.
" Administration at a specific concentration and dosage.
" Not harmful if properly used; plausible efficacy and pharmaco-
logical effects based on long-term experience and usage.
THMPs may be granted market authorization through simplified
registration not requiring preclinical and clinical studies.
The application for a THMP registration must therefore be ac-
companied by all the required information for MA for a medicinal
product, with the exception of clinical data and experimental
preclinical data, and must include as well:
" Bibliographical evidence that the product has a traditional use
(if an EMA monograph exists, it can be used as a certification
for the traditional use for the submitted indications).
" Bibliographical and expert reports on the medicinesʼ safety.
" Registration application or MA for the product obtained in an
EU member state or other country, and all the information
regarding any refusal received in an EU member state or other
country, including the explanation of the decision leading to
that outcome.
The primary objective of Directive 2004/24/EC was to ensure
quality and safety of these products and clearly define therapeu-
tic indications. For this purpose, an EMA HMPC has been estab-
lished and is actively working on the elaboration of lists of herbal
substances, vegetal preparations and combination products, and
plant extract monographs. More than 150 monographs have al-
ready been published, all supported by a full bibliographic review
on quality, safety, and efficacy for each plant extract. Despite this
huge effort at the European level, the transposition of this legal
intent is still pending in many European countries. The registra-tion of botanicals as drugs is not a centralized procedure and it is
left to national agencies by means of a national or mutual recog-
nition procedure [Council Regulation (EEC) No 2309/93]. Many
agencies are still skeptical towards botanical drugs and the regis-
tration process is expensive and extremely slow, wasting a real
market opportunity. Furthermore, the European Food Safety
Authority (EFSA) suspended its opinion on botanical claims and
criteria that should be adopted to avoid ambiguity and define
clear links between food supplements and HMPs, which are still
confused. The result is that still unregistered products, food sup-
plements, and HMPs coexist in many markets, often with the
same dosage and indications. Finally, an additional issue is repre-
sented by the increasing number of medical devices with thera-
peutic claims based on botanical active principles on the market.
This is allowed if the main mechanism of action is physical (i.e.,
the formation of a polymeric film that acts to protect the muco-
sa). In this case, therapeutic effects can be accepted and the dos-
sier to obtain the EC mark has to include some demonstration,
even bibliographical, of clinical efficacy and safety.
In this context, it is worth considering that as long as this regula-
tory environment for the registration of HMPs remains un-
changed, the majority of novel opportunities will remain in the
food area or other parallel registration tracks and will therefore
be left out of the pharmaceutical area, which indeed should be
the most obvious for HMPs.
On the other hand, borderline situations are growing and multi-
plying in order to findmarket opportunities for innovative phyto-
active principles that do not find their natural way in being ac-
knowledged as medicinal products.
With this regard, a relatively recent hope for a potential opening
to reconsider “natural multicomponent products” as proper
pharmaceuticals and avoid the “classical” single-component ap-
proach is represented by the US “Botanical Drug Products-Guid-
ance for industry”. This Guidance was officially delivered in June
2004 by the FDA through the Center for Drug Evaluation and
Research (CDER) and very recently updated [12]. The declared
purpose of the Guidance is to consider botanical drugsʼ special
features and through further adjustment during the FDA review
process, to “facilitate” the development of new therapies from
botanical sources. These therapies are intended for use in the di-
agnosis, cure, mitigation, treatment, or prevention of diseases in
humans. It is also worthwhile to consider that the FDA Guidance
has been proposed concomitantly to the existence of a dietary
supplement market where all herbal preparations are included
and which does not pose a pre-marketing approval. In this con-
text, botanicals contained in dietary supplements already on the
US market could theoretically be upgraded to pharmaceuticals
according to the FDA Guidance.
According to the Guidance, a botanical drug can be defined as a
product that contains vegetable materials as ingredients, includ-
ing plant materials, algae, macroscopic fungi, or combinations
thereof. It may be available as (but not limited to) a solution
(e.g., tea), powder, tablet, capsule, elixir, topical, or injectable.
Fermentation products, highly purified (or chemically modified)
botanical substances, genetically modified plants, allergenic ex-
tracts, and vaccines containing botanical ingredients are not con-
templated.
Based on the requirements defined by the Guidance, multicom-
ponent botanical products with previous utilization both in the
USA and/or other countries can be considered for initiating a
proof of concept phase II clinical investigation, with a limited
dossier.Minghetti P et al. Innovation in Phytotherapy:… Planta Med 2016; 82: 591–595
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l.According to FDA guidelines for industry, the development path
for botanical drug products consists of the following steps [13]:
" Discovery phase: screening, ethnobotany, bioinformatics.
" Plant acquisition, genotype selection, optimization.
" Product characterization, extraction method development,
optimization, standardization.
" In vitro and in vivo efficacy validation.
" IND application to FDA.
" Clinical development (Phase 1 and Phase 2).
" Additional toxicology, mode of action, pharmacokinetics, drug
interactions.
" Quality system (QS)/current good manufacturing practice
(CGMP) protocols.
" Clinical development (Phase 3).
" New drug application (NDA) approval by FDA.
" Commercialization.
In particular, the CMC section does not include a “mandatory” re-
quest to identify the active components of the product, and
therefore further purifications are not required. On the other
hand, additional quality controls are requested for initial rawma-
terials and the product to be tested in clinical studies. Preclinical
investigation requirements are limited and even preclinical toxi-
cology may be replaced by evidence of previous human use and
can therefore be postponed to further development steps, usually
within phase III. Theoretically, this simplified approach is signifi-
cantly shortening the full length of the development of a botani-
cal drug as compared to the “classical” pharmaceutical develop-
ment of new molecular entities.
In fact, the Pharma way to develop NCEs/NBEs requires many
years (approximately 15): from the first to the fifth year, the focus
is the research target identification; from the fifth to the seventh
year, the target is the discovery lead identification and optimiza-
tion; and from the seventh to the fifteenth year, the target is the
development at preclinical and clinical phases. Through the new
approach is based on traditional experience, considering that
much information is available, the registration is achieved in ap-
proximately eight years. The value of this difference is shortened
research and discovery leveraging ancient knowledge and faster
clinical development including earlier phase II trials as proofs of
concept.
Like with other “innovative” changes, the newly introduced
Guidance has also encountered a relatively slow grade of accep-
tance by the pharmaceutical environment. As of today, only
two products have been finally registered under its umbrella:
Veregen® for the treatment of genital warts (2006) and, more
recently, Fulizaq® for the treatment of HIV-associated diarrhea
(2012). Nevertheless, an increasing number of INDs have been
submitted in the last years, showing that the level of acceptance
of this new opportunity is gradually growing.
In addition, recent agreements between big multinational com-
panies and smaller companies with a portfolio of traditionally
used multicomponent botanical products have been established
with the specific aim of developing new botanical drugs, taking
advantage of the Guidance.
Finally, it is also worth to note that Chinese and Indian govern-
ments, and more recently also South Korean authorities, are
strongly suggesting that local companies consider the US Guid-
ance as a potential channel for “modernizing” traditional Chinese
medicine, Indian Ayurveda, and Korean traditional medicine, re-
spectively, considering the possibility to validate old traditional
formulas mostly based on multicomponent products in a West-
ern country. As a concrete result of this policy, an impressiveMinghetti P et al. Innovation in Phytotherapy:… Planta Med 2016; 82: 591–595number of INDs have been submitted to the FDA by Chinese, In-
dian, and South Korean companies, sometimes through American
subsidiaries.Closing Remarks and Authorsʼ Proposal
!
Looking at this rapidly evolving scenario with the eyes of Euro-
pean companies committed to pharmaceutical innovation, it is
like feeling a “lost opportunity”. At the present time, the regula-
tory European scenario for phytotherapy is wasting efforts in the
difficult task of properly registering and harmonizing the old
medicinal products while scarcely considering the traditional
enormous portfolio of commonly utilized products as a potential
“reservoir” of innovation when they are not addressed according
to the “magic bullet” paradigm [14]. In fact, the two existing
directives [Traditional Herbal Medicine (article 16a, Directive
2004/24/EC) and Well Established Use (art 10a, Directive 2001/
83/EC)], by definition, are both aimed at recognizing the option
of a “simplified” pharmaceutical registration only if the products
have proven long-term usage, in the first case, or based on evi-
dence from previous randomized controlled clinical trials, in the
second case. This should be seen as a first step to harmonize the
market and properly register HMPs. The following step should be
the “simplified” option in order to create innovation in the field
of phytotherapy by starting to consider traditionally used multi-
component products or their improved formulations as new bo-
tanical drugs to be developed. In fact, the THMP legislation limits
the registration as medicinal products to herbal compounds with
the indications approved by the HMPC and reported in the
monograph (for mild, self-medication pathologic conditions and
short-period treatment). To facilitate the MA of HMPs with some
innovations, the requirement of a full dossier seems to be not
needed in terms of safety and efficacy guarantee, and registration
can be quickened using a hybrid application. According to article
10 (3) of the Directive 2001/83/EC, a medicinal product having
new active substances, new therapeutic indications, strength,
pharmaceutical form, or route of administration with respect to
a reference medicinal product can be authorized with a hybrid
application, providing some new data from preclinical and clini-
cal studies. This legal basis may be considered applicable also to
herbal preparations as long as theWEU is assumed as a reference
medicinal product. Instead, the THMP does not fall into the strict
definition of a reference medicinal product given by the EMA,
since a full dossier is missing (l" Table 1). Updated guidelines
allowing a hybrid recording for THMPs with a certain grade of
innovation in terms of manufacturing or therapeutic indication
would increase the grade of acceptance of this trend. These
guidelines would define a possible simplification to be granted
in terms of characterization, preclinical studies, and clinical trials.
For example, while completely new plants have to be character-
ized in terms of safety with the requirement of a full preclinical
toxicological evaluation, plants for which there is evidence of
use should benefit from a simplified access to phase II, evenwhen
proposed for new indications.
In this context, we suggest European authorities consider this
potential opportunity and evaluate a more flexible approach for
the future in order to help have more innovative therapeutic op-
tions available based on the huge portfolio of traditional rem-
edies belonging to our phytotherapy armamentarium without
forgetting the legacy from extra-European medical approaches
when a large amount of safety data is available.
595PerspectivesMoreover, it is clear that a speed-up of the registration of THMPs
and WEU herbal derivatives with some grade of innovation
would allow an appropriate environment to create new and in-
novative therapeutic uses for HMPs.rig
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6 Silano V, Coppens P, Larrañaga-Guetaria A, Minghetti P, Roth-Ehrang R.
Regulations applicable to plant food supplements and related products
in the European Union. Food Funct 2011; 2: 710–7197 Bilia AR.Herbal medicinal products versus botanical-food supplements
in the European market: state of art and perspectives. Nat Prod Com-
mun 2015; 10: 125–131
8 Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and
challenges for the metabolite profiling of complex natural extracts.
J Chromatogr A 2015; 1382: 136–164
9 Bilia AR. Science meets regulation. J Ethnopharmacol 2014; 158: 487–
494
10 European Medicines Agency. Guideline on the use of the CTD format in
the preparation of a registration application for traditional herbal
medicinal products. EMA/HMPC/71049/2007, Rev. 2; 2015. Available
at http://www.ema.europa.eu/docs/en_GB/document_library/Regula-
tory_and_procedural_guideline/2015/04/WC500185353.pdf. Accessed
February 22, 2016
11 Knöss W, Chinou I. Regulation of medicinal plants for public health –
European community monographs on herbal substances. Planta Med
2012; 78: 1311–1316
12 U.S. Department of Health and Human Services, Food and Drug Adminis-
tration, Center for Drug Evaluation and Research (CDER). Botanical Drug
Development Guidance for Industry, Revision 1: August 2015 (Pharma-
ceutical Quality/CMC). Available at http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM458484.pdf. Accessed February 22, 2016
13 Schmidt BM, Ribnicky DM, Lipsky E, Raskin I. Revisiting the ancient con-
cept of botanical therapeutics. Nat Chem Biol 2007; 3: 360–366
14 Fürst R, Zündorf I. Evidence-based phytotherapy in Europe: where do
we stand? Planta Med 2015; 81: 962–967Minghetti P et al. Innovation in Phytotherapy:… Planta Med 2016; 82: 591–595
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i M
ila
no
. C
op
y
